

Express Mail Label: EV 541426595 US

Date of Deposit: Sept.8, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Mail Stop IDS, P.O. Box 1450, Alexandria, VA 22313-1450

Ann-Ellice Parker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Hetzel et al.

Docket No.: SENS0002

Serial No.10/702,236

Art Unit: 3736

Filed: 11/5/2003

Examiner: Unknown

Title: A METHOD OF SCREENING FOR DISORDERS OF GLUCOSE METABOLISM

SEPTEMBER 8, 2004

TRANSMITTAL FORM

Commissioner of Patents Mail Stop IDS P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The following documents are being transmitted:

- IDS Transmittal (1 sheet);
- Information Disclosure Statement, (2 pgs) 1449 form (2 pgs)
- International Search Report
- Return Postcard

Applicant believes that there is no fee due with this submission. However, the Commissioner is authorized to charge any additional fees that may be due and credit any overpayments to Deposit Account No. 07-1445 (Order No. SENS0002CIP). A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Michael A. Glenn Reg. No. 30,176

Customer No. 22862



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hetzel, et al. Docket No.: SENS0002

Filed: November 5, 2003 Examiner: Unknown

Title: A METHOD OF SCREENING FOR DISORDERS OF GLUCOSE METABOLISM

Assistant Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 SEPTEMBER 8, 2004

issue fee)

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is submitted:

(X) under 37 CFR 1.97(b), or
(within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
under 37 CFR 1.97(c) together with either a:
() Certification under 37 CFR 1.97(e), or
() a \$220.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
() under 37 CFR 1.97(d) together with a:
() Certification under 37 CFR 1.97(e), and
() a \$220.00 fee under 37 CFR 1.17(d)(2)(ii), and
() a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1)

(X) The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 07-1445 (Order No. SENS0002CIP). A copy of this sheet is enclosed for accounting purposes.

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the

(X) Applicant(s) submit herewith Form PTO 1449 -- Information Disclosure Citation together with copies of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.25.

() A concise explanation of the relevance of foreign language patents, foreign language publications and other foreign language information listed on PTO Form 1449, as presently understood by the individual(s) designated in 37 CFR 156(c) most knowledgeable about the content is given on the attached sheet, or where a foreign language patent is cited in a search report or other action by a foreign patent office in a counterpart foreign application, an English language version of the search report or action which indicates the degree of relevance found by the foreign office is listed on form PTO 1449 and is enclosed herewith.

It is requested that the information disclosed herein be made of record in this application.

Respectfully Submitted,

Michael Glenn Attorney For Applicant Reg. No. 30,176

Customer No. 22862

PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/702,236		
Filing Date	11/5/2003		
First Named Inventor	Hetzel et al.		
Art Unit	3736		
Examiner Name	Unknown		
Attorney Docket Number	SENS0002		

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	<u> </u>	Number-Kind Code ^{2 (# known)}		······································	Figures Appear	
		US-				
•		US-	•			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		*		
		US-				
		US-				
	†	US-				
		US-				
		US-		-		
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Т
						Ļ
		•				╄
						╄
						╁
	<u> </u>					₽

Examiner	Date	
Signature	Considered	
- 9		•

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (02-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Constitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
The state of the s	Application Number	10/702/236		
INFORMATION DISCLOSURE	Filing Date	11/05/2003		
STATEMENT BY APPLICANT	First Named Inventor	Hetzel et al.		
(Use as many sheets as necessary)	Art Unit	3736		
(USE as many sneets as necessary)	Examiner Name	Unknown		
Sheet 2 of 2	Attorney Docket Number	SENS0002		

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
٠	Α	LEYVA et al., "Factors of the Metabolic Syndrome", Arteriosclerosis Thrombotic Vascular Biology, 1998, Vol.18, pgs 208-214, especially pg. 209	
	В	TAMAYO et al., "Interpreting patterns of gene expression with self-organizing maps"; Proceedings of the National Academy of Sciences of the United States of America. March 1999, Vol. 96, pgs. 2907-2912, especially pg. 2909.	
	С	DECODE Study Group; "Is fasting glucose sufficent to define diabetes?" Epidemiological data from 20 European studies. Diabetologia 1999, Vol. 42, pgs. 647-654, especially pg. 648	
	D	SVANBORG et al. "Associations between Plasma Glucose and DSM-II R Cluster B Personality Traits in Psychiatric Outpatients" Neuropsychobiology, 2000, Vol. 41, pgs. 79-87, especially Material and Methods	
	E	BONORA et al., "Impaired Glucose Tolerance, Type II diabetes mellitus and cartoid atherosclerosis: prospective results from Bruneck Study", Diabetologia, 2000, Vol. 43, pps. 156-164, especially Material and Methods.	
	F	YOUNG - HYMAN et al. "Evaluation of the Insulin Resistance Syndrome in 5 to 10 year old Overweight/Obese African American Children. Daibetes Care, August 2001, Vol. 24, No.: 8, pgs. 1359-1364, especially pg. 1360	
	G	FENEBERG et al. "Altered Temporal Organization of Plasma Insulin Oscillations in Chronic Renal Failure", The Journal of Clinical Endocrinology & Metabolism. May 2002, Vol. 87, No.: 5, pgs. 1965-1973, especially Materials and Methods	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.